Related Experiment Video
Updated: Apr 9, 2026
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines
Kazue Ito1,2,3, Noriko Ishida4, Shin Ito2,3
1Department of Head and Neck Medical Oncology, Miyagi Cancer Center Hospital, Natori, Miyagi, Japan.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is a major cancer among head and neck malignancies with a limited availability of effective molecularly targeted therapies. The underlying oncogenic mechanisms, however, remain poorly understood. To investigate patient-specific molecular targets, we established patient-derived cell (PDC) lines from surgically resected HNSCC tissue samples. We performed comprehensive analyses, including driver gene mutation profiling using a multigene panel, transcriptomic profiling, and karyotyping. Various cancer-associated genomic alterations, primarily copy number gains, were identified, and these findings were consistent with those of previous studies. Notably, the amplification of EGFR, FGFR2, and CCND1 was associated with their overexpression, suggesting potential tumor driver roles. A PDC with a PIK3CA activating mutation was sensitive to the PI3K inhibitor Alpelisib. We also demonstrated that PDCs harboring chromosome segregation errors were vulnerable to KIF18A deletion and pharmacological inhibition. These results support the value of HNSCC-derived PDCs as a platform for advances in precision medicine in oncology research.
Insights
Patient-derived cell lines from head and neck squamous cell carcinoma (HNSCC) reveal molecular targets for precision medicine. These models identified vulnerabilities to targeted therapies, advancing oncology research.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge due to limited effective molecularly targeted therapies.
- The intricate oncogenic mechanisms driving HNSCC remain incompletely understood, hindering the development of novel treatments.
Purpose of the Study:
- To establish and characterize patient-derived cell (PDC) lines from HNSCC tissue for investigating patient-specific molecular targets.
- To identify potential therapeutic vulnerabilities and driver mutations within HNSCC through comprehensive genomic and transcriptomic analyses.
Main Methods:
- Generation of patient-derived cell (PDC) lines from surgically resected HNSCC tissue.
- Comprehensive molecular profiling including driver gene mutation analysis, transcriptomic profiling, and karyotyping.
- Functional validation of identified targets and drug sensitivities in established PDC lines.
Main Results:
- Genomic analyses revealed cancer-associated alterations, including copy number gains consistent with previous studies.
- Amplification of EGFR, FGFR2, and CCND1 correlated with their overexpression, suggesting roles as potential tumor drivers.
- A PIK3CA-mutated PDC line demonstrated sensitivity to the PI3K inhibitor Alpelisib, and PDCs with chromosomal instability were vulnerable to KIF18A inhibition.
Conclusions:
- HNSCC-derived PDCs serve as a valuable platform for advancing precision medicine in oncology.
- The identified molecular alterations and drug sensitivities in PDCs offer potential avenues for targeted HNSCC therapies.
- This study underscores the importance of patient-specific models in understanding HNSCC pathogenesis and developing tailored treatment strategies.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
